1 week ago
2
PROTECT YOURSELF with Orgo-Life® QUANTUM TECHNOLOGY
Orgo-Life the new way to the future Advertising by AdpathwayArticle content
Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
VANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its third quarter 2026 financial results after market close on November 9, 2026.
Article content
Article content
Consistent with its current practice, Zymeworks does not plan to host a conference call or webcast for its third quarter 2026 financial results. Management looks forward to engaging with the investment community at upcoming events.
Article content
Advertisement 1
Article content
Investor Conference Participation
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
Zymeworks also announced that management will participate in the following upcoming investor conferences:
Article content
- 8th Annual Wolfe Research Healthcare Conference: Management will participate in one-on-one meetings and a fireside chat on November 10 in New York, NY.
- Stifel 2026 Healthcare Conference: Management will participate in one-on-one meetings and a fireside chat on November 11 in New York, NY.
- Truist Securities BioPharma Symposium: Management will participate in one-on-one meetings on November 12 in New York, NY.
- 2026 Jefferies Global Healthcare Conference: Management will participate in one-on-one meetings and a fireside chat on November 17 in London, UK.
Article content
A live webcast of certain fireside chats will be available in the Investors section of the Zymeworks website at www.zymeworks.com, and a replay will be available following the events.
Article content
About Zymeworks Inc.
Article content
Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets designed to generate durable cash flows while advancing innovative medicines for difficult-to-treat diseases. The Company’s asset and royalty aggregation strategy combines a growing portfolio of commercial and near-commercial assets, including YUPELRI® (revefenacin), with a differentiated internal research and development engine. Zymeworks’ portfolio also includes Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using Zymeworks’ proprietary antibody engineering technologies.
Article content
Advertisement 2
Article content
Zymeworks is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric™ platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. These capabilities, together with Zymeworks’ integrated drug development expertise, enable the Company to develop differentiated therapeutics and create value through both internal innovation and strategic partnerships.
Article content
For more information about Zymeworks, its portfolio and pipeline, visit www.zymeworks.com and follow @ZymeworksInc on X.
Article content
Contacts:
Article content
Investor Inquiries:
Shrinal Inamdar
Vice President, Investor Relations
(604) 678-1388
[email protected]
Article content
Media Inquiries:
Diana Papove
Vice President, Corporate Communications
(604) 678-1388
[email protected]
Article content
Article content
Article content
Article content
Article content
Article content
English (US) · 
French (CA) · 
French (FR) ·